Life Science Incubation at LabCentral/BioLabs with Partners Extending from the USA to Europe.

Q1 Pharmacology, Toxicology and Pharmaceutics

Handbook of experimental pharmacology Pub Date : 2024-01-01 DOI:10.1007/164_2024_727

Johannes Fruehauf

引用次数: 0

Abstract

This chapter provides a blueprint for accelerating biotech and life sciences innovation using public-private partnerships to create innovation infrastructure that become a platform for scientific breakthroughs and economic growth. Examples are provided on creating standalone co-working labs as well as through partnerships with academic and healthcare system partners both in the United States and Europe. Risks and challenges are addressed as well as the overall benefits to the broader public of investing public funds in biotech and life science infrastructure versus individual companies based on the potential impact to global public health from new treatments, therapies, devices, and diagnostics.

查看原文本刊更多论文

在 LabCentral/BioLabs 进行生命科学孵化，合作伙伴从美国扩展到欧洲。

本章为利用公私合作伙伴关系加快生物技术和生命科学创新提供了一个蓝图，以创建创新基础设施，使其成为科学突破和经济增长的平台。本章举例说明了在美国和欧洲创建独立的联合办公实验室以及与学术界和医疗保健系统合作伙伴建立伙伴关系的情况。根据新疗法、新疗法、新设备和新诊断方法对全球公共卫生的潜在影响，探讨了将公共资金投入生物技术和生命科学基础设施与单个公司相比所面临的风险和挑战，以及对广大公众的整体利益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Handbook of experimental pharmacology Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)

CiteScore

5.20

自引率

0.00%

发文量

期刊介绍： The Handbook of Experimental Pharmacology is one of the most authoritative and influential book series in pharmacology. It provides critical and comprehensive discussions of the most significant areas of pharmacological research, written by leading international authorities. Each volume in the series represents the most informative and contemporary account of its subject available, making it an unrivalled reference source.